Metabolic oral medication for Alzheimer's disease
Part of Brain & nervous system clinical trials.
This study tests an oral medication that may change how the body processes energy to help people with early Alzheimer's disease. It aims to see if the treatment can slow down memory loss and improve daily function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 50 and 85 years old.
- You have a confirmed diagnosis of Alzheimer's disease or mild cognitive impairment due to Alzheimer's, with a positive biomarker test (like a PET scan or spinal fluid test).
- Your memory test score is within a certain range, depending on your education level.
- You have a caregiver who can spend at least 4 days a week with you and come to study visits.
- If you take Alzheimer's medications, your dose has been stable for at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests an oral medicine (EX039) to see if it can help people with mild Alzheimer’s disease. It focuses on slowing or improving thinking and memory problems over time.
This trial tests a special supplement combination designed to support brain energy use in people with Alzheimer's. It aims to see if the supplement can help slow cognitive decline.
This study tests an oral tablet (TTYP01) for people with early Alzheimer's disease. It aims to see if the drug can slow memory loss. You must have a study partner who can support you throughout the trial.
This study tests an experimental drug for Alzheimer's called NTRX-07. It aims to see if it can slow memory decline for people with mild to moderate Alzheimer's.
This study tests an experimental drug (KarXT) to see if it safely reduces agitation in people with Alzheimer's disease. It may help if you or your loved one experiences restlessness, aggression, or irritability related to Alzheimer's.
This study tests an experimental drug called RO7568282 for people in the early stages of Alzheimer's disease. The goal is to see if it is safe and whether it can slow down memory loss and thinking problems.
Hear when a new Alzheimer s Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.